Bamco Inc. NY Buys Shares of 25,000 Xenon Pharmaceuticals Inc. $XENE

Bamco Inc. NY acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 25,000 shares of the biopharmaceutical company's stock, valued at approximately $1,509,000.

Several other large investors have also added to or reduced their stakes in the stock. Danske Bank A S purchased a new stake in Xenon Pharmaceuticals in the third quarter valued at approximately $32,000. Kestra Advisory Services LLC bought a new stake in Xenon Pharmaceuticals during the fourth quarter worth about $33,000. Osaic Holdings Inc. lifted its stake in Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company's stock worth $40,000 after purchasing an additional 1,034 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Xenon Pharmaceuticals during the fourth quarter valued at approximately $43,000. Finally, Rockefeller Capital Management L.P. raised its stake in shares of Xenon Pharmaceuticals by 450.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,100 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 900 shares in the last quarter. Institutional investors own 95.45% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on XENE. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. JPMorgan Chase & Co. lifted their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 27th. Needham & Company LLC dropped their target price on Xenon Pharmaceuticals from $80.00 to $78.00 and set a "buy" rating for the company in a report on Friday, May 8th. Royal Bank Of Canada cut their target price on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an "outperform" rating on the stock in a report on Friday, August 7th. Finally, HC Wainwright reissued a "buy" rating and set a $74.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday, August 10th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $77.13.

Insider Activity at Xenon Pharmaceuticals

In related news, Director Steven Gannon sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $64.06, for a total transaction of $640,600.00. Following the completion of the sale, the director owned 1,870 shares of the company's stock, valued at $119,792.20. This trade represents a 84.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gary Patou sold 1,322 shares of the business's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the transaction, the director owned 24,896 shares of the company's stock, valued at approximately $1,322,973.44. The trade was a 5.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 12,512 shares of company stock valued at $774,088. 2.91% of the stock is owned by insiders.

Xenon Pharmaceuticals Stock Down 2.9%

NASDAQ XENE opened at $61.93 on Friday. The stock's 50 day moving average is $63.04 and its 200 day moving average is $56.36. The firm has a market capitalization of $5.99 billion, a PE ratio of -13.07 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a twelve month low of $35.60 and a twelve month high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, topping analysts' consensus estimates of ($1.16) by $0.05. During the same quarter in the previous year, the company earned ($1.07) earnings per share. On average, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source